EUCTR2010-021986-60-LV进行中（未招募）不适用
A Pilot study to evaluate the Efficacy and Safety of GFT505 (80mg) orally administered once daily for 12 weeks in patients with Type 2 Diabetes mellitus.A Multicentre, Randomised, Double Blind, Placebo-Controlled study.
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- GENFIT
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must meet all of the following inclusion criteria to be eligible for enrolment into the trial:
- •1. Provide written informed consent prior to enrolment.
- •2. Male or post-menopausal female (defined as >12 months since last menstrual period) or surgical menopause. If hormonal replacement therapy, it should be stable at least for 6 months prior to screening.
- •3. Aged from 18 to 75 years.
- •4. BMI =27 and =45 kg/m².
- •5. Drug-Naive patients with type 2 diabetes mellitus (non insulin dependent diabetes). Patients should not be treated by insulin or other diabetes medication for the last 3 months prior to screening. Patients treated for less than 4 weeks with insulin may be included in the study.
- •6. Non-hypertensive or patient taking antihypertensive medication (except non-permitted medication) maintained at a stable dosage at least for 2 months prior to screening (and the stable dosage can be maintained throughout the study).
- •7. Patient agrees to come to following visits inside the protocol specified range.
- •In addition to the above criteria, these following inclusion criteria must be fulfilled according to B1 lab results:
- •8. HbA1c = 7.0% and <9.5%.
- •9. Anti-GAD negative for patients aged less than 40 years.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients presenting with any of the following exclusion criteria will not be included in the trial:
- •1. Type I Diabetes Mellitus.
- •2. Patients who have one or more of the following: symptoms of poorly controlled diabetes (drastic weight loss, polyuria-polydypsia) according to the investigator’s opinion, a history of diabetic ketoacidosis or hyperosmolar nonketosic coma.
- •3. Severe macular oedema requiring photocoagulation or specific treatment.
- •4. Known Heart Failure (Grade I to IV of NYHA classification).
- •5. Patients who had an acute cardiovascular episode within the 6 months previous to the start of the trial, or with a history of coronary angioplasty, history of stroke, TIA (Transient Ischemic Attack)], Coronary Heart Disease (Angina pectoris, history of myocardial infarction, revascularisation procedures)
- •6. Blood Pressure > 160 / 95 mmHg.
- •7. Evidence of any other unstable or untreated clinically significant immunological, neoplastic, endocrine, haematological, gastrointestinal, hepatic, neurological or psychiatric abnormalities or medical disease.
- •8. Patients who have serious or unstable medical or psychological conditions which, in the opinion of the Investigator, would lead the patient to be non-compliant or uncooperative during the study or would compromise the patient’s safety or successful participation in the study
- •9. Known alcohol and/or any other drug abuse or dependence. Alcohol consumption of more than 3 alcoholic beverages per day is considered abusive. One alcoholic beverage is defined as 30 mL distilled spirits, 120 mL wine, or 330 mL beer.
- •10. Patients who have donated blood or blood products within the previous month prior to screening or who plan to donate blood or blood products at any time during the trial and in the 3 months following the end of the study.
- •11. The Patient is a female of childbearing potential, is pregnant or lactating.
- •12. Known intolerance or contra-indication to the list of excipients of GFT505 (Gelatin, Lactose monohydrate, Titanium dioxide, Red Iron Oxide, Magnesium Stearate).
- •13. Patient not covered by Health Insurance System and/or not in compliance with the recommendations of National Law in force.
- •14. Patient who cannot be contacted in case of emergency.
- •15. Any medication that may interfere with study medication absorption, distribution, metabolism or excretion or could lead to induction or inhibition of microsomial enzymes within 3 months prior to screening
- •16. Insulin or other anti-diabetic medication. Patients treated for less than 4 weeks
- •with insulin may be included in the study.
- •17. Lipid-lowering drugs such as fibrates.
- •18. Currently taking other investigational drugs or who have taken part in a clinical trial within the previous month prior to screening.
- •In addition to the above criteria, patient should not present any of the following exclusion criteria according to B1 lab results:
- •19. Fasting Plasma Glucose (FPG) = 240 mg/dL
- •20. TG > 400 mg/dL
- •21. Alanine aminotransferase (ALT), Aspartate aminotransferase (AST) and Gamma glutamyltransferase (GGT) >3 X the upper limit of normal (ULN).
- •22. Positive screening for HBsAg or HCV
- •23. Uncontrolled hypothyroidism defined as TSH > 2X the upper limit of normal (ULN). Thyroid dysfunction controlled for at least 6 months prior to screening is permitted.
- •24. Significant renal disease, including nephritic syndrome, chronic renal failure (defined as creatinine clearance < 60mL/mn according to MDRD formula and serum creatinine >180Wmol/L).
研究者
相似试验
进行中（未招募）
1 期
A Pilot study to evaluate the Efficacy and Safety of GFT505 orally administered once daily (30 mg) for 28 days in atherogenic dyslipidaemic patients with abdominal obesity. A double blind, placebo-controlled and randomized study.EUCTR2007-004337-41-FRGENFIT30
进行中（未招募）
1 期
A Pilot study to evaluate the Efficacy and Safety of GFT505 (80mg) orally administered once daily for 35 days in patients presenting with impaired glucose tolerance and abdominal obesity. A double blind, parallel group, placebo-controlled and randomized study.patients presenting with impaired glucose tolerance and abdominal obesityMedDRA version: 9.1Level: LLTClassification code 10036481Term: Pre-diabetesMedDRA version: 9.1Level: LLTClassification code 10059179Term: Abdominal obesityEUCTR2009-011003-23-FRGENFIT40
进行中（未招募）
1 期
A Pilot study to evaluate the Efficacy and Safety of GFT505 (80 mg) orally administered once daily for 28 days in atherogenic dyslipidaemic patients with abdominal obesity. A double blind, placebo-controlled and randomized study.Atherogenic dyslipidaemic patients with abdominal obesityMedDRA version: 9.1Level: LLTClassification code 10058108Term: DyslipidaemiaMedDRA version: 9.1Level: LLTClassification code 10059179Term: Abdominal obesityEUCTR2008-005779-86-FRGENFIT90
进行中（未招募）
1 期
A Pilot study to evaluate the Efficacy and Safety of GFT505 (30 mg) orally administered for 28 days in patients with Frederickson Type IIb Dyslipidemia (Mixed Hyperlipidemia). A double blind, placebo-controlled and randomized study.EUCTR2007-003237-16-FRGENFIT30
尚未招募
不适用
A Pilot study to Evaluate the Efficacy and Safety of Autologous Adipose tissue-derived Stromal Vascular Fraction(SVF) treatment for the Patients with articular cartilage injury of the kneeKCT0005566Samsung Medical Center3